Pharmacology

statins, venous thromboembolism, VTE, atherosclerotic disease, antiplatelet therapyvenous thromboembolism, VTE, atherosclerotic disease, antiplatelet therapy

statins, venous thromboembolism, VTE, atherosclerotic disease, antiplatelet therapyvenous thromboembolism, VTE, atherosclerotic disease, antiplatelet therapy

statins, venous thromboembolism, VTE, atherosclerotic disease, antiplatelet therapyvenous thromboembolism, VTE, atherosclerotic disease, antiplatelet therapy

heart disease, smoking, clopidogrel, prasugrel, TRITON-TIMI, EXCELSIOR, percutaneous coronary intervention, PCIheart disease, smoking, clopidogrel, prasugrel, TRITON-TIMI, EXCELSIOR, percutaneous coronary intervention, PCI

heart disease, smoking, clopidogrel, prasugrel, TRITON-TIMI, EXCELSIOR, percutaneous coronary intervention, PCIheart disease, smoking, clopidogrel, prasugrel, TRITON-TIMI, EXCELSIOR, percutaneous coronary intervention, PCI

heart disease, smoking, clopidogrel, prasugrel, TRITON-TIMI, EXCELSIOR, percutaneous coronary intervention, PCIheart disease, smoking, clopidogrel, prasugrel, TRITON-TIMI, EXCELSIOR, percutaneous coronary intervention, PCI

hypertension, combination therapy, blood pressure control, BP control, role of combination antihypertensive agents, cardiovascular disease, thiazide, angiotensin-converting enzyme inhibitor, potassium-sparing diuretichypertension, combination therapy, blood pressure control, BP control, role of combination antihypertensive agents, cardiovascular disease, thiazide, angiotensin-converting enzyme inhibitor, potassium-sparing diuretic

hypertension, combination therapy, blood pressure control, BP control, role of combination antihypertensive agents, cardiovascular disease, thiazide, angiotensin-converting enzyme inhibitor, potassium-sparing diuretichypertension, combination therapy, blood pressure control, BP control, role of combination antihypertensive agents, cardiovascular disease, thiazide, angiotensin-converting enzyme inhibitor, potassium-sparing diuretic

hypertension, combination therapy, blood pressure control, BP control, role of combination antihypertensive agents, cardiovascular disease, thiazide, angiotensin-converting enzyme inhibitor, potassium-sparing diuretichypertension, combination therapy, blood pressure control, BP control, role of combination antihypertensive agents, cardiovascular disease, thiazide, angiotensin-converting enzyme inhibitor, potassium-sparing diuretic

antidepressants, depression, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), gerontology, aging, drug interactions antidepressants, depression, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), gerontology, aging, drug interactions

antidepressants, depression, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), gerontology, aging, drug interactions antidepressants, depression, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), gerontology, aging, drug interactions

antidepressants, depression, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), gerontology, aging, drug interactions antidepressants, depression, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), gerontology, aging, drug interactions

bisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, traumabisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, trauma

bisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, traumabisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, trauma

bisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, traumabisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, trauma

first trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant usefirst trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant use

first trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant usefirst trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant use

first trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant usefirst trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant use

metastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registrymetastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registry

metastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registrymetastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registry

metastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registrymetastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registry

breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17

breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17

breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17

serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders

serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders

serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders

cardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safetycardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safety

cardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safetycardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safety

cardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safetycardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safety